Home » Healthcare » Cancer Biological Therapy Market

Cancer Biological Therapy Market By Therapeutic Approach (Monoclonal Antibodies (mAbs), Tyrosine Kinase Inhibitors (TKIs), Immune Checkpoint Inhibitors, Cytokines, Cancer Vaccines, Gene Therapy, Oncolytic Viruses, Others) By Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Leukemia and Lymphoma, Melanoma, Prostate Cancer, Other Cancer Types) – Growth, Future Prospects & Competitive Analysis, 2016 – 2030

Summary
Table Of Content

Market Insights

The global demand for cancer biological therapy was valued at USD 111945.8 Million in 2022 and is expected to reach USD 199652.8 Million in 2030, growing at a CAGR of 7.5% between 2023 and 2030.
The monoclonal antibodies (mAbs) segment is the market leader by therapeutic approach, accounting for more than 30% of total value in 2022, while the immune checkpoint inhibitors segment is estimated to grow rapidly in the projection period.
The lung cancer category is expected to expand quickly in the forecast period, while the breast cancer segment had the largest market share in 2022.
The adult patient demographics segment dominates the global need for cancer biological therapy, accounting for more than 65% in 2022 and is predicted to expand at a high CAGR.
The hospitals category dominated the market with 35% of the total revenue share by end-users. In contrast, the cancer clinics category will expand fastest over the projected time frame.
North America is driving the growth of the cancer biological therapy market, accounting for more than one-third of the market in 2022, while Asia Pacific and Europe account for relatively less than 54% of the market in 2022. Europe had a market revenue share of more than 20% in 2022.
The cancer biological therapy industry is expanding as a result of expanded patient assistance programs (PAPs), increasing government cancer awareness campaigns, rising cancer prevalence worldwide, and substantial R&D funding from big corporations.
According to the IARC (International Agency for Research on Cancer), there will be 16.3 million cancer-related deaths and 27.5 million new cancer cases across the globe by 2040. Cancer is the leading cause of death in the world.
The majority of cancer cases are caused by factors related to lifestyle, such as drinking and smoking, as well as dietary substances, including polyaromatic hydrocarbons and nitrites.
The market is closely connected to diagnostic and genomic sequencing technologies, as well as supportive care services, all of which contribute to the holistic approach to cancer treatments.

Executive Summary

Market Definition

The cancer biological therapy market involves the development, production, and sale of therapeutic products and treatments that utilize biological substances or living organisms to target and treat cancer. These products are designed to intervene in the growth, progression, or spread of cancer by leveraging the body’s natural processes, the immune system, or specific molecular pathways. Cancer biological therapies include a range of approaches, such as immunotherapies, targeted therapies, gene therapies, and other biologically-based treatments. These therapies are often personalized to the individual patient based on their specific cancer type, genetic profile, and other factors, with the aim of achieving more effective and less toxic treatments compared to traditional chemotherapy and radiation therapy. The cancer biological therapy market encompasses a diverse array of products and services, from monoclonal antibodies and cellular therapies to vaccines and supportive care medications, all aimed at improving outcomes and quality of life for cancer patients.

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

Market Overview

The global cancer biological therapy market has witnessed rapid growth in recent years and is expected to grow at a CAGR of 7.5% between 2023 and 2030. The market was valued at USD 111945.8 million in 2022 and is expected to reach USD 199652.8 million in 2030.

Cancer biological therapy is an advanced cancer treatment method that employs a living creature. These life forms are created in a laboratory to treat a malignant infection, or they are taken from living cells. There are numerous biological treatments available, including monoclonal antibodies, interleukins, interferon, and vaccines. The therapy fundamentally addresses cancer by directly or indirectly utilizing the body’s immune system. The market for cancer biological therapy is predicted to expand due to an increase in confirmed cases of cancer and the number of specialized cancer treatment facilities around the world.

Patients 65 years of age or older make up 58% of all newly diagnosed cancer cases in economically developed countries, compared to 40% in poor countries, according to the Global Cancer Observatory (GCO). When countries are ranked according to GDP, cancer ranks as the third top cause of death in countries with low or moderate incomes and as the second leading cause of death in those with high incomes. In addition, higher exposure to external carcinogenic substances, as well as growing alcohol and tobacco use, will increase the risk of developing cancer, driving higher market need for cancer biological therapy.

Segmentation by Therapeutic Approach

The immune checkpoint inhibitors segment is anticipated to demonstrate the highest CAGR in the forecast period. Immune checkpoint inhibitors, such as PD-L1 and PD-1 inhibitors, have shown remarkable effectiveness in a wide range of cancer types, driving their increasing adoption.
Monoclonal antibodies (mAbs) currently dominate the market share, commanding over 30% in 2022. Monoclonal antibodies have been at the forefront of cancer biological therapy due to their precision in targeting cancer cells and minimizing harm to healthy tissues. The established usage of mAbs in various malignancies, such as breast and colorectal cancer, has contributed largely to their market dominance.

Segmentation by Cancer Type

The lung cancer segment is anticipated to register the highest CAGR in the coming years. Lung cancer is one of the most prevalent and deadly cancer types globally, necessitating a growing demand for advanced therapies, including biological treatments.
Breast cancer leads the market, with a share of over 25% in 2022. The high incidence of breast cancer and extensive research efforts focused on developing targeted therapies for this cancer type have contributed to its dominant market position.

Segmentation by End User

Hospitals constitute the dominant category, accounting for more than 35% of the global cancer biological therapy market demand in 2022. Hospitals are the primary centers for cancer diagnosis, treatment, and patient care, making them the leading end users of cancer biological therapies.
The cancer clinics segment complements the healthcare ecosystem by providing specialized cancer care and fulfills the remaining cancer biological therapy market needs. These clinics play a key role in delivering customized treatments and follow-up care to cancer patients.

Segmentation by Patient Demographics

Pediatric patients are projected to exhibit the highest CAGR, reflecting the growing focus on pediatric oncology and the development of biological therapies tailored to this patient group. Advances in pediatric cancer research and the need for safer and more effective treatments for children are fueling this growth.
Adults currently lead the market share, accounting for over 65% in 2022. The prevalence of cancer among the adult population, coupled with the broader range of cancer types affecting this demographic, underscores their substantial presence in the market.

Segmentation by Region

North America’s robust healthcare infrastructure and research capabilities make it a highly lucrative region, holding over one-third of the global cancer biological therapy market share in 2022. The presence of leading pharmaceutical companies and extensive clinical trial activity contribute to this regional dominance in the worldwide market.
Asia Pacific and Europe collectively contribute to nearly 54% of the market share, with the Asia Pacific region displaying significant growth potential. The Asia Pacific’s expanding healthcare infrastructure, rising cancer incidence, and increasing access to innovative treatments position it as a key growth region.
Europe maintains a substantial share of over 20% in the same year, reflecting its established medical facilities, robust market presence, and emphasis on research & development activities.
The rest of the world, encompassing regions like Latin America, the Middle East, and Africa, contributes to the remaining demand for cancer biological therapy, offering untapped growth opportunities in emerging markets as healthcare access and awareness continue to improve.

North America is home to some of the world’s leading research institutions, pharmaceutical companies, and biotechnology firms that drive innovation in cancer biological therapies. These entities benefit from substantial funding, a strong talent pool, and a culture of scientific discovery. The well-established healthcare systems in North America, particularly in the U.S. and Canada, facilitate access to these therapies. Adequate reimbursement mechanisms and private insurance coverage make it financially feasible for patients to receive cancer biological treatments. Major pharmaceutical companies headquartered in North America have robust oncology divisions and extensive portfolios of cancer biological therapies. Their global reach and distribution networks also contribute to the regional market dominance.

Over the projection period, the Asia Pacific is estimated to be the fastest-growing market for cancer biological therapy. The region has been experiencing an increasing burden of cancer due to factors such as population growth, aging, and lifestyle changes, which drive the demand for advanced cancer treatments like biological therapies. Rapid economic development in nations like China and India has boosted spending on healthcare and expanded access to cutting-edge remedies like cancer biological therapy. Many governments in the Asia Pacific are taking steps to improve cancer care and invest in R&D operations, promoting a favorable environment for the adoption of biological therapies.

Key Highlights of the Report

The global cancer biological therapy market is segmented by therapeutic approach, cancer type, end user, patient demographics, and region. Within the therapeutic approach segment, monoclonal antibodies (mAbs) dominate the global market, known for their precision in targeting cancer cells. Breast cancer type leads the market, reflecting extensive research and targeted therapy development. Hospitals are the primary end users, while cancer clinics play an important role in delivering specialized care and addressing remaining market needs. Moreover, adult patient demographics currently constitute the majority of the market revenue share.

The increased disease burden and prevalence of cancer around the world will have a substantial impact on the outlook for the cancer biological therapy industry. Cancer was responsible for over 10 million fatalities in 2020, as reported by the WHO. As per the National Institute of Cancer, cancer-related deaths will reach 16.4 million per year by 2040, with 29.5 million new cases diagnosed each year in the United States. Furthermore, fast-paced lives and increased consumption of highly processed foods, as well as a major spike in alcohol consumption, have resulted in a high incidence of risk factors like obesity and type 2 diabetes. This scenario highlights the importance of developed biological therapies for limiting or preventing tumor growth and spread.

North America held the largest market and is likely to dominate the market throughout the forecasting period due to its solid healthcare infrastructure, substantial R&D investments, and widespread adoption of innovative healthcare technologies. The leading regional pharmaceutical and biotechnology companies drive advancements in biologic therapies. The high prevalence of cancer cases and increased awareness among patients and healthcare professionals further increase regional market demand for biological treatments. Furthermore, the Asia Pacific region is expected to witness strong growth in the market, supported by rising cancer rates, increased healthcare spending, and improved healthcare facilities in countries such as India, Japan, and China.

What Are The Main Drivers Of The Global Cancer Biological Therapy Market?

The rising incidence of cancer globally, rising demand for more precise and effective cancer treatments, developments in biotechnology and genomics enabling personalized medicine, a strong pipeline of cutting-edge biological therapies, increased investment in cancer R&D, and expanding access to healthcare in emerging markets are the main factors driving the global market for cancer biological therapies. Moreover, the shift towards immunotherapy and precision medicine approaches, along with a rising aging population, continue to fuel the market’s growth as they drive the development and adoption of novel biological treatments for various cancer types.

What Are The Major Challenges Faced By The Global Cancer Biological Therapy Market?

The major challenges faced by the global cancer biological therapy market encompass stringent regulatory requirements and lengthy approval processes, high development costs, limited accessibility due to the often-outrageous pricing of biologics, potential adverse side effects associated with immunotherapies, and the ongoing need for comprehensive biomarker research to identify the most suitable patient populations. Additionally, the intricate nature of biologics production poses limitations related to manufacturing consistency and supply chain management.

What Are The Growth Opportunities In The Global Cancer Biological Therapy Market?

The global cancer biological therapy market offers substantial growth opportunities, driven by increasing research & development efforts, a focus on expanding the application of biologics to various cancer types, and the potential for combination therapies. Moreover, the adoption of precision medicine and genomics continues to create opportunities for customized treatments, while the emergence of biosimilars enhances affordability and market competition. Furthermore, the rising incidence of cancer in developing regions, advancements in diagnostics, and the integration of artificial intelligence for treatment optimization and patient monitoring are expected to propel market growth.

Market Drivers

Several factors drive the global cancer biological therapy market. The following are the key drivers of the global cancer biological therapy market:

Emerging Advancements in Immunotherapy

Immunotherapy has emerged as a revolutionary approach to cancer treatments, and it represents a major driver of the global cancer biological therapy market developments. Immunotherapies including CAR-T cell treatments, monoclonal antibodies, and immune checkpoint inhibitors (such PD-1 and PD-L1 inhibitors) have demonstrated extraordinary success in using the body’s immune system to target and eradicate cancer cells. These therapies work by blocking inhibitory signals in the immune system or by directly enhancing immune responses against cancer.

Immunotherapies are more successful than conventional medicines like chemotherapy because they may target cancer cells with precision while protecting healthy organs. As research & development in immunotherapy continue to progress, including the exploration of combination therapies and the identification of new immune targets, the market is driven by the increasing adoption of these innovative and personalized treatment options.

Market Restraints

The global cancer biological therapy market faces challenges that may hinder its growth. These include the following:

Higher Treatment Costs

One of the primary restraints in the global cancer biological therapy market is the high cost associated with these innovative treatments. Biological therapies, including immunotherapies and targeted therapies, often involve complex manufacturing processes, specialized technologies, and significant research and development investments. As a result, the price tags for these therapies can be prohibitively expensive, making them unaffordable for many patients, even in developed countries with established healthcare systems. The cost of cancer care, including biological therapies, can impose a substantial financial burden on patients and their families. This high cost also raises concerns among healthcare systems and payers about sustainability and budget constraints.

Opportunities

The global cancer biological therapy market offers significant growth opportunities. These include the following:

Expanding Applications to Various Cancer Types

A key opportunity in the cancer biological therapy industry is the expansion of these therapies to a broader range of cancer types. Historically, cancer biological therapies were primarily developed for specific malignancies. However, ongoing research is revealing the potential effectiveness of biological treatments across a wider spectrum of cancer types. For example, immunotherapies like checkpoint inhibitors have shown promise in treating multiple cancer types, including lung, melanoma, bladder, and kidney cancers. For use in treating different solid tumours and haematological malignancies, targeted treatments such kinase inhibitors and monoclonal antibodies are being investigated. This expansion of applications can lead to increased market growth by addressing unmet medical needs and providing more treatment options for a broader patient population.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Competitive Landscape

Key Players

The competitive landscape of the global cancer biological therapy market is characterized by intense competition among pharmaceutical companies, biotech firms, and research institutions. The following are some of the top market players and their market shares:

F. Hoffmann-La Roche Ltd
Mylan N.V.
Teva Pharmaceutical Industries Ltd
Sanofi
Pfizer Inc
GSK Plc
Novartis AG
Bayer AG
Merck & Co. Inc
Sun Pharmaceutical Industries Ltd
Aurobindo Pharma
Lupin
Endo Pharmaceuticals Plc
Zydus Group
Bausch Health Companies Inc
Others

These companies are heavily invested in R&D activities to develop innovative biological therapies, with a focus on immunotherapies, targeted therapies, and combination treatments. They are also actively exploring opportunities in emerging markets, especially in Asia Pacific, due to rising cancer rates and improving healthcare infrastructure. Leading market players are addressing concerns about patient access by offering patient assistance programs, exploring value-based pricing models, and working with healthcare systems to improve affordability.

In May 2022, Biocon Biologics and Viatris, formerly Mylan, launched the cancer drug bevacizumab in Canada under the brand name Abevmy.

In May 2021, LUMAKRASTM (Sotorasib), the first & only targeted therapy for KRAS G12C-mutated locally advanced or recurrent non-small cell lung cancer, received FDA approval.

Summary of Key Findings

The global cancer biological therapy market has been experiencing significant growth, owing to the increasing cancer prevalence, advancements in biological treatments, and a shift towards targeted therapies.
Market segmented by therapeutic approach, cancer type, end user, patient demographics, and region.
Immunotherapies, particularly immune checkpoint inhibitors and CAR-T cell therapies, have transformed cancer treatment by leveraging the body’s immune system to target cancer cells more effectively.
Lung cancer type is expected to witness the highest growth rate due to its high prevalence and the demand for advanced therapies.
Hospitals are the primary end users, while cancer clinics complement the healthcare ecosystem.
Liquid biopsy tests, which analyze circulating tumor DNA and other biomarkers from a blood sample, are gaining importance for early cancer detection and treatment monitoring.
The development of biological therapies for pediatric cancers is gaining attention, addressing the unique needs and challenges of treating cancer in children.
High treatment costs and regulatory limitations remain key challenges in the global market.

Future Outlook

The global cancer biological therapy market is expected to continue its growth trajectory, driven by ongoing research, technological advancements, and the increasing demand for more effective and targeted cancer treatments.
Pediatric oncology is an emerging area of focus, with increasing efforts to develop biological therapies specifically tailored to children.
The Asia Pacific area is expected to be the fastest-growing market, owing to an increase in cancer diagnoses, improved healthcare infrastructure, and more access to novel treatments.
Research institutions are exploring combination therapies that involve using multiple biological agents or a combination of biological and traditional therapies to enhance treatment effectiveness.
The increasing global aging population is further expected to propel demand for cancer treatments, including biological therapies, as cancer incidence tends to rise with age.

Segmentation

By Therapeutic Approach
- Monoclonal Antibodies (mAbs)
- Tyrosine Kinase Inhibitors (TKIs)
- Immune Checkpoint Inhibitors
- Cytokines
- Cancer Vaccines
- Gene Therapy
- Oncolytic Viruses
- Others
By Cancer Type
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Leukemia and Lymphoma
- Melanoma
- Prostate Cancer
- Other Cancer Types
By End User
- Hospitals
- Cancer Clinics
- Research Institutions
By Patient Demographics
- Pediatric
- Adult
By Region
- North America
  - U.S.
  - Canada
  - Mexico
- Europe
  - Germany
  - France
  - U.K.
  - Italy
  - Spain
  - Rest of Europe
- Asia Pacific
  - China
  - Japan
  - India
  - South Korea
  - South-east Asia
  - Rest of Asia Pacific
- Latin America
  - Brazil
  - Argentina
  - Rest of Latin America
- Middle East & Africa
  - GCC Countries
  - South Africa
  - Rest of the Middle East and Africa

Adjacent Markets

Several adjacent markets have high revenue growth opportunities in the cancer biological therapy market. The key adjacent markets for cancer biological therapy market –

1. Preface

1.1. Report Description

1.1.1. Purpose of the Report

1.1.2. Target Audience

1.1.3. USP and Key Offerings

1.2. Research Scope

1.3. Market Introduction

2. Executive Summary

2.1. Market Snapshot: Global Cancer Biological Therapy Market

2.1.1. Global Cancer Biological Therapy Market, By Therapeutic Approach

2.1.2. Global Cancer Biological Therapy Market, By Cancer Type

2.1.3. Global Cancer Biological Therapy Market, By End User

2.1.4. Global Cancer Biological Therapy Market, By Patient Demographics

2.1.5. Global Cancer Biological Therapy Market, By Region

2.2. Insights from Primary Respondents

3. Market Dynamics & Factors Analysis

3.1. Introduction

3.1.1. Global Cancer Biological Therapy Market Value, 2017-2030, (US$ Mn)

3.1.2. Y-o-Y Growth Trend Analysis

3.2. Market Dynamics

3.2.1. Cancer Biological Therapy Market Drivers

3.2.2. Cancer Biological Therapy Market Restraints

3.2.3. Cancer Biological Therapy Market Opportunities

3.2.4. Major Cancer Biological Therapy Industry Challenges

3.3. Growth and Development Patterns

3.4. Investment Feasibility Analysis

3.5. Market Opportunity Analysis

3.5.1. Therapeutic Approach

3.5.2. Cancer Type

3.5.3. End User

3.5.4. Patient Demographics

3.5.5. Geography

4. Market Competitive Landscape Analysis

4.1. Company Market Share Analysis, 2022

4.1.1. Global Cancer Biological Therapy Market: Company Market Share, Value 2022

4.1.2. Global Cancer Biological Therapy Market: Top 6 Company Market Share, Value 2022

4.1.3. Global Cancer Biological Therapy Market: Top 3 Company Market Share, Value 2022

4.2. Global Cancer Biological Therapy Market: Company Revenue Share Analysis, 2022

4.3. Company Assessment Metrics, 2022

4.3.1. Stars

4.3.2. Emerging Leaders

4.3.3. Pervasive Players

4.3.4. Participants

4.4. Startups/SMEs Assessment Metrics, 2022

4.4.1. Progressive Companies

4.4.2. Responsive Companies

4.4.3. Dynamic Companies

4.4.4. Starting Blocks

4.5. Strategic Development

4.5.1. Acquisition and Mergers

4.5.2. New Product Launch

4.5.3. Regional Expansion

4.5.4. Partnerships

4.6. Key Player Product Matrix

4.7. Potential for New Players in the Global Cancer Biological Therapy Market

5. Premium Insights

5.1. STAR (Situation, Task, Action, Results) Analysis

5.2. Porter’s Five Forces Analysis

5.2.1. Threat of New Entrants

5.2.2. Bargaining Power of Buyers/Consumers

5.2.3. Bargaining Power of Suppliers

5.2.4. Threat of Substitute Types

5.2.5. Intensity of Competitive Rivalry

5.3. PESTEL Analysis

5.3.1. Political Factors

5.3.2. Economic Factors

5.3.3. Social Factors

5.3.4. Technological Factors

5.3.5. Environmental Factors

5.3.6. Legal Factors

5.4. Key Market Trends

5.4.1. Demand Side Trends

5.4.2. Supply Side Trends

5.5. Value Chain Analysis

5.6. Technology Analysis

5.6.1. Research and development in the global market

5.6.2. Patent Analysis

5.6.3. Emerging technologies and their potential disruption to the market

5.7. Consumer Behaviour Analysis

5.7.1. Consumer Preferences and Expectations

5.7.2. Factors Influencing Consumer Buying Decisions

5.7.2.1. North America

5.7.2.2. Europe

5.7.2.3. Asia Pacific

5.7.2.4. Latin America

5.7.2.5. Middle East and Africa

5.7.3. Consumer Pain Points

5.8. Analysis and Recommendations

5.9. Adjacent Market Analysis

6. Market Positioning of Key Players, 2022

6.1. Company market share of key players, 2022

6.2. Competitive Benchmarking

6.3. Market Positioning of Key Vendors

6.4. Geographical Presence Analysis

6.5. Major Strategies Adopted by Key Players

6.5.1. Key Strategies Analysis

6.5.2. Mergers and Acquisitions

6.5.3. Partnerships

6.5.4. Product Launch

6.5.5. Geographical Expansion

6.5.6. Others

7. Impact Analysis of COVID-19 and Russia – Ukraine War on Cancer Biological Therapy Market

7.1. Ukraine-Russia War Impact

7.1.1. Uncertainty and Economic Instability

7.1.2. Supply chain disruptions

7.1.3. Regional market shifts

7.1.4. Shift in government priorities

7.2. COVID-19 Impact Analysis

7.2.1. Supply Chain Disruptions

7.2.2. Demand Fluctuations

7.2.3. Shift in Product Mix

7.2.4. Reduced Industrial Activity

7.2.5. Regional Impact Analysis

7.2.5.1. North America

7.2.5.2. Europe

7.2.5.3. Asia Pacific

7.2.5.4. Latin America

7.2.5.5. Middle East and Africa

8. Global Cancer Biological Therapy Market, By Therapeutic Approach

8.1. Global Cancer Biological Therapy Market Overview, by Therapeutic Approach

8.1.1. Global Cancer Biological Therapy Market Revenue Share, By Therapeutic Approach, 2022 Vs 2030 (in %)

8.2. Monoclonal Antibodies (mAbs)

8.2.1. Global Cancer Biological Therapy Market, By Monoclonal Antibodies (mAbs), By Region, 2017-2030 (US$ Mn)

8.2.2. Market Dynamics for Monoclonal Antibodies (mAbs)

8.2.2.1. Drivers

8.2.2.2. Restraints

8.2.2.3. Opportunities

8.2.2.4. Trends

8.3. Tyrosine Kinase Inhibitors (TKIs)

8.3.1. Global Cancer Biological Therapy Market, By Tyrosine Kinase Inhibitors (TKIs), By Region, 2017-2030 (US$ Mn)

8.3.2. Market Dynamics for Tyrosine Kinase Inhibitors (TKIs)

8.3.2.1. Drivers

8.3.2.2. Restraints

8.3.2.3. Opportunities

8.3.2.4. Trends

8.4. Immune Checkpoint Inhibitors

8.4.1. Global Cancer Biological Therapy Market, By Immune Checkpoint Inhibitors, By Region, 2017-2030 (US$ Mn)

8.4.2. Market Dynamics for Immune Checkpoint Inhibitors

8.4.2.1. Drivers

8.4.2.2. Restraints

8.4.2.3. Opportunities

8.4.2.4. Trends

8.5. Cytokines

8.5.1. Global Cancer Biological Therapy Market, By Cytokines, By Region, 2017-2030 (US$ Mn)

8.5.2. Market Dynamics for Cytokines

8.5.2.1. Drivers

8.5.2.2. Restraints

8.5.2.3. Opportunities

8.5.2.4. Trends

8.6. Cancer Vaccines

8.6.1. Global Cancer Biological Therapy Market, By Cancer Vaccines, By Region, 2017-2030 (US$ Mn)

8.6.2. Market Dynamics for Cancer Vaccines

8.6.2.1. Drivers

8.6.2.2. Restraints

8.6.2.3. Opportunities

8.6.2.4. Trends

8.7. Gene Therapy

8.7.1. Global Cancer Biological Therapy Market, By Gene Therapy, By Region, 2017-2030 (US$ Mn)

8.7.2. Market Dynamics for Gene Therapy

8.7.2.1. Drivers

8.7.2.2. Restraints

8.7.2.3. Opportunities

8.7.2.4. Trends

8.8. Oncolytic Viruses

8.8.1. Global Cancer Biological Therapy Market, By Oncolytic Viruses, By Region, 2017-2030 (US$ Mn)

8.8.2. Market Dynamics for Oncolytic Viruses

8.8.2.1. Drivers

8.8.2.2. Restraints

8.8.2.3. Opportunities

8.8.2.4. Trends

8.9. Others

8.9.1. Global Cancer Biological Therapy Market, By Others, By Region, 2017-2030 (US$ Mn)

8.9.2. Market Dynamics for Others

8.9.2.1. Drivers

8.9.2.2. Restraints

8.9.2.3. Opportunities

8.9.2.4. Trends

9. Global Cancer Biological Therapy Market, By Cancer Type

9.1. Global Cancer Biological Therapy Market Overview, by Cancer Type

9.1.1. Global Cancer Biological Therapy Market Revenue Share, By Cancer Type, 2022 Vs 2030 (in %)

9.2. Breast Cancer

9.2.1. Global Cancer Biological Therapy Market, By Breast Cancer, By Region, 2017-2030 (US$ Mn)

9.2.2. Market Dynamics for Breast Cancer

9.2.2.1. Drivers

9.2.2.2. Restraints

9.2.2.3. Opportunities

9.2.2.4. Trends

9.3. Lung Cancer

9.3.1. Global Cancer Biological Therapy Market, By Lung Cancer, By Region, 2017-2030 (US$ Mn)

9.3.2. Market Dynamics for Lung Cancer

9.3.2.1. Drivers

9.3.2.2. Restraints

9.3.2.3. Opportunities

9.3.2.4. Trends

9.4. Colorectal Cancer

9.4.1. Global Cancer Biological Therapy Market, By Colorectal Cancer, By Region, 2017-2030 (US$ Mn)

9.4.2. Market Dynamics for Colorectal Cancer

9.4.2.1. Drivers

9.4.2.2. Restraints

9.4.2.3. Opportunities

9.4.2.4. Trends

9.5. Leukemia and Lymphoma

9.5.1. Global Cancer Biological Therapy Market, By Leukemia and Lymphoma, By Region, 2017-2030 (US$ Mn)

9.5.2. Market Dynamics for Leukemia and Lymphoma

9.5.2.1. Drivers

9.5.2.2. Restraints

9.5.2.3. Opportunities

9.5.2.4. Trends

9.6. Melanoma

9.6.1. Global Cancer Biological Therapy Market, By Melanoma, By Region, 2017-2030 (US$ Mn)

9.6.2. Market Dynamics for Melanoma

9.6.2.1. Drivers

9.6.2.2. Restraints

9.6.2.3. Opportunities

9.6.2.4. Trends

9.7. Prostate Cancer

9.7.1. Global Cancer Biological Therapy Market, By Prostate Cancer, By Region, 2017-2030 (US$ Mn)

9.7.2. Market Dynamics for Prostate Cancer

9.7.2.1. Drivers

9.7.2.2. Restraints

9.7.2.3. Opportunities

9.7.2.4. Trends

9.8. Other Cancer Types

9.8.1. Global Cancer Biological Therapy Market, By Other Cancer Types, By Region, 2017-2030 (US$ Mn)

9.8.2. Market Dynamics for Other Cancer Types

9.8.2.1. Drivers

9.8.2.2. Restraints

9.8.2.3. Opportunities

9.8.2.4. Trends

10. Global Cancer Biological Therapy Market, By End User

10.1. Global Cancer Biological Therapy Market Overview, by End User

10.1.1. Global Cancer Biological Therapy Market Revenue Share, By End User, 2022 Vs 2030 (in %)

10.2. Hospitals

10.2.1. Global Cancer Biological Therapy Market, By Hospitals, By Region, 2017-2030 (US$ Mn)

10.2.2. Market Dynamics for Hospitals

10.2.2.1. Drivers

10.2.2.2. Restraints

10.2.2.3. Opportunities

10.2.2.4. Trends

10.3. Cancer Clinics

10.3.1. Global Cancer Biological Therapy Market, By Cancer Clinics, By Region, 2017-2030 (US$ Mn)

10.3.2. Market Dynamics for Cancer Clinics

10.3.2.1. Drivers

10.3.2.2. Restraints

10.3.2.3. Opportunities

10.3.2.4. Trends

10.4. Research Institutions

10.4.1. Global Cancer Biological Therapy Market, By Research Institutions, By Region, 2017-2030 (US$ Mn)

10.4.2. Market Dynamics for Research Institutions

10.4.2.1. Drivers

10.4.2.2. Restraints

10.4.2.3. Opportunities

10.4.2.4. Trends

11. Global Cancer Biological Therapy Market, By Patient Demographics

11.1. Global Cancer Biological Therapy Market Overview, by Patient Demographics

11.1.1. Global Cancer Biological Therapy Market Revenue Share, By Patient Demographics, 2022 Vs 2030 (in %)

11.2. Pediatric

11.2.1. Global Cancer Biological Therapy Market, By Pediatric, By Region, 2017-2030 (US$ Mn)

11.2.2. Market Dynamics for Pediatric

11.2.2.1. Drivers

11.2.2.2. Restraints

11.2.2.3. Opportunities

11.2.2.4. Trends

11.3. Adult

11.3.1. Global Cancer Biological Therapy Market, By Adult, By Region, 2017-2030 (US$ Mn)

11.3.2. Market Dynamics for Adult

11.3.2.1. Drivers

11.3.2.2. Restraints

11.3.2.3. Opportunities

11.3.2.4. Trends

12. Global Cancer Biological Therapy Market, By Region

12.1. Global Cancer Biological Therapy Market Overview, by Region

12.1.1. Global Cancer Biological Therapy Market, By Region, 2022 vs 2030 (in%)

12.2. Therapeutic Approach

12.2.1. Global Cancer Biological Therapy Market, By Therapeutic Approach, 2017-2030 (US$ Mn)

12.3. Cancer Type

12.3.1. Global Cancer Biological Therapy Market, By Cancer Type, 2017-2030 (US$ Mn)

12.4. End User

12.4.1. Global Cancer Biological Therapy Market, By End User, 2017-2030 (US$ Mn)

12.5. Patient Demographics

12.5.1. Global Cancer Biological Therapy Market, By Patient Demographics, 2017-2030 (US$ Mn)

13. North America Cancer Biological Therapy Market Analysis

13.1. Overview

13.1.1. Market Dynamics for North America

13.1.1.1. Drivers

13.1.1.2. Restraints

13.1.1.3. Opportunities

13.1.1.4. Trends

13.2. North America Cancer Biological Therapy Market, by Therapeutic Approach, 2017-2030(US$ Mn)

13.2.1. Overview

13.2.2. SRC Analysis

13.3. North America Cancer Biological Therapy Market, by Cancer Type, 2017-2030(US$ Mn)

13.3.1. Overview

13.3.2. SRC Analysis

13.4. North America Cancer Biological Therapy Market, by End User, 2017-2030(US$ Mn)

13.4.1. Overview

13.4.2. SRC Analysis

13.5. North America Cancer Biological Therapy Market, by Patient Demographics, 2017-2030(US$ Mn)

13.5.1. Overview

13.5.2. SRC Analysis

13.6. North America Cancer Biological Therapy Market, by Country, 2017-2030 (US$ Mn)

13.6.1. North America Cancer Biological Therapy Market, by Country, 2022 Vs 2030 (in%)

13.6.2. U.S.

13.6.3. Canada

13.6.4. Mexico

14. Europe Cancer Biological Therapy Market Analysis

14.1. Overview

14.1.1. Market Dynamics for North America

14.1.1.1. Drivers

14.1.1.2. Restraints

14.1.1.3. Opportunities

14.1.1.4. Trends

14.2. Europe Cancer Biological Therapy Market, by Therapeutic Approach, 2017-2030(US$ Mn)

14.2.1. Overview

14.2.2. SRC Analysis

14.3. Europe Cancer Biological Therapy Market, by Cancer Type, 2017-2030(US$ Mn)

14.3.1. Overview

14.3.2. SRC Analysis

14.4. Europe Cancer Biological Therapy Market, by End User, 2017-2030(US$ Mn)

14.4.1. Overview

14.4.2. SRC Analysis

14.5. Europe Cancer Biological Therapy Market, by Patient Demographics, 2017-2030(US$ Mn)

14.5.1. Overview

14.5.2. SRC Analysis

14.6. Europe Cancer Biological Therapy Market, by Country, 2017-2030 (US$ Mn)

14.6.1. Europe Cancer Biological Therapy Market, by Country, 2022 Vs 2030 (in%)

14.6.2. UK

14.6.3. France

14.6.4. Germany

14.6.5. Italy

14.6.6. Spain

14.6.7. Benelux

14.6.8. Russia

14.6.9. Rest of Europe

15. Asia Pacific Cancer Biological Therapy Market Analysis

15.1. Overview

15.1.1. Market Dynamics for North America

15.1.1.1. Drivers

15.1.1.2. Restraints

15.1.1.3. Opportunities

15.1.1.4. Trends

15.2. Asia Pacific Cancer Biological Therapy Market, by Therapeutic Approach, 2017-2030(US$ Mn)

15.2.1. Overview

15.2.2. SRC Analysis

15.3. Asia Pacific Cancer Biological Therapy Market, by Cancer Type, 2017-2030(US$ Mn)

15.3.1. Overview

15.3.2. SRC Analysis

15.4. Asia Pacific Cancer Biological Therapy Market, by End User, 2017-2030(US$ Mn)

15.4.1. Overview

15.4.2. SRC Analysis

15.5. Asia Pacific Cancer Biological Therapy Market, by Patient Demographics, 2017-2030(US$ Mn)

15.5.1. Overview

15.5.2. SRC Analysis

15.6. Asia Pacific Cancer Biological Therapy Market, by Country, 2017-2030 (US$ Mn)

15.6.1. Asia Pacific Cancer Biological Therapy Market, by Country, 2022 Vs 2030 (in%)

15.6.2. China

15.6.3. Japan

15.6.4. India

15.6.5. South Korea

15.6.6. South East Asia

15.6.7. Rest of Asia Pacific

16. Latin America Cancer Biological Therapy Market Analysis

16.1. Overview

16.1.1. Market Dynamics for North America

16.1.1.1. Drivers

16.1.1.2. Restraints

16.1.1.3. Opportunities

16.1.1.4. Trends

16.2. Latin America Cancer Biological Therapy Market, by Therapeutic Approach, 2017-2030(US$ Mn)

16.2.1. Overview

16.2.2. SRC Analysis

16.3. Latin America Cancer Biological Therapy Market, by Cancer Type, 2017-2030(US$ Mn)

16.3.1. Overview

16.3.2. SRC Analysis

16.4. Latin America Cancer Biological Therapy Market, by End User, 2017-2030(US$ Mn)

16.4.1. Overview

16.4.2. SRC Analysis

16.5. Latin America Cancer Biological Therapy Market, by Patient Demographics, 2017-2030(US$ Mn)

16.5.1. Overview

16.5.2. SRC Analysis

16.6. Latin America Cancer Biological Therapy Market, by Country, 2017-2030 (US$ Mn)

16.6.1. Latin America Cancer Biological Therapy Market, by Country, 2022 Vs 2030 (in%)

16.6.2. Brazil

16.6.3. Argentina

16.6.4. Rest of Latin America

17. Middle East Cancer Biological Therapy Market Analysis

17.1. Overview

17.1.1. Market Dynamics for North America

17.1.1.1. Drivers

17.1.1.2. Restraints

17.1.1.3. Opportunities

17.1.1.4. Trends

17.2. Middle East Cancer Biological Therapy Market, by Therapeutic Approach, 2017-2030(US$ Mn)

17.2.1. Overview

17.2.2. SRC Analysis

17.3. Middle East Cancer Biological Therapy Market, by Cancer Type, 2017-2030(US$ Mn)

17.3.1. Overview

17.3.2. SRC Analysis

17.4. Middle East Cancer Biological Therapy Market, by End User, 2017-2030(US$ Mn)

17.4.1. Overview

17.4.2. SRC Analysis

17.5. Middle East Cancer Biological Therapy Market, by Patient Demographics, 2017-2030(US$ Mn)

17.5.1. Overview

17.5.2. SRC Analysis

17.6. Middle East Cancer Biological Therapy Market, by Country, 2017-2030 (US$ Mn)

17.6.1. Middle East Cancer Biological Therapy Market, by Country, 2022 Vs 2030 (in%)

17.6.2. UAE

17.6.3. Saudi Arabia

17.6.4. Rest of Middle East

18. Africa Cancer Biological Therapy Market Analysis

18.1. Overview

18.1.1. Market Dynamics for North America

18.1.1.1. Drivers

18.1.1.2. Restraints

18.1.1.3. Opportunities

18.1.1.4. Trends

18.2. Africa Cancer Biological Therapy Market, by Therapeutic Approach, 2017-2030(US$ Mn)

18.2.1. Overview

18.2.2. SRC Analysis

18.3. Africa Cancer Biological Therapy Market, by Cancer Type, 2017-2030(US$ Mn)

18.3.1. Overview

18.3.2. SRC Analysis

18.4. Africa Cancer Biological Therapy Market, by End User, 2017-2030(US$ Mn)

18.4.1. Overview

18.4.2. SRC Analysis

18.5. Africa Cancer Biological Therapy Market, by Patient Demographics, 2017-2030(US$ Mn)

18.5.1. Overview

18.5.2. SRC Analysis

18.6. Africa Cancer Biological Therapy Market, by Country, 2017-2030 (US$ Mn)

18.6.1. Middle East Cancer Biological Therapy Market, by Country, 2022 Vs 2030 (in%)

18.6.2. South Africa

18.6.3. Egypt

18.6.4. Rest of Africa

19. Company Profiles

19.1. F. Hoffmann-La Roche Ltd

19.1.1. Company Overview

19.1.2. Products/Services Portfolio

19.1.3. Geographical Presence

19.1.4. SWOT Analysis

19.1.5. Financial Summary

19.1.5.1. Market Revenue and Net Profit (2019-2022)

19.1.5.2. Business Segment Revenue Analysis

19.1.5.3. Geographical Revenue Analysis

19.2. Mylan N.V.

19.3. Teva Pharmaceutical Industries Ltd

19.4. Sanofi

19.5. Pfizer Inc

19.6. GSK Plc

19.7. Novartis AG

19.8. Bayer AG

19.9. Merck & Co. Inc

19.10. Sun Pharmaceutical Industries Ltd

19.11. Aurobindo Pharma

19.12. Lupin

19.13. Endo Pharmaceuticals Plc

19.14. Zydus Group

19.15. Bausch Health Companies Inc

19.16. Others

20. Research Methodology

20.1. Research Methodology

20.2. Phase I – Secondary Research

20.3. Phase II – Data Modelling

20.3.1. Company Share Analysis Model

20.3.2. Revenue Based Modelling

20.4. Phase III – Primary Research

20.5. Research Limitations

20.5.1. Assumptions

List of Figures

FIG. 1 Global Cancer Biological Therapy Market: Research Methodology

FIG. 2 Market Size Estimation – Top Down & Bottom Up Approach

FIG. 3 Global Cancer Biological Therapy Market Segmentation

FIG. 4 Global Cancer Biological Therapy Market, by Therapeutic Approach, 2022 (US$ Mn)

FIG. 5 Global Cancer Biological Therapy Market, by Cancer Type, 2022 (US$ Mn)

FIG. 6 Global Cancer Biological Therapy Market, by End User, 2022 (US$ Mn)

FIG. 7 Global Cancer Biological Therapy Market, by Patient Demographics, 2022 (US$ Mn)

FIG. 8 Global Cancer Biological Therapy Market, by Geography, 2022 (US$ Mn)

FIG. 9 Attractive Investment Proposition, by Therapeutic Approach, 2022

FIG. 10 Attractive Investment Proposition, by Cancer Type, 2022

FIG. 11 Attractive Investment Proposition, by End User, 2022

FIG. 12 Attractive Investment Proposition, by Patient Demographics, 2022

FIG. 13 Attractive Investment Proposition, by Geography, 2022

FIG. 14 Global Market Share Analysis of Key Cancer Biological Therapy Market Manufacturers, 2022

FIG. 15 Global Market Positioning of Key Cancer Biological Therapy Market Manufacturers, 2022

FIG. 16 Global Cancer Biological Therapy Market Value Contribution, By Therapeutic Approach, 2022 & 2030 (Value %)

FIG. 17 Global Cancer Biological Therapy Market, by Monoclonal Antibodies (mAbs), Value, 2017-2030 (US$ Mn)

FIG. 18 Global Cancer Biological Therapy Market, by Tyrosine Kinase Inhibitors (TKIs), Value, 2017-2030 (US$ Mn)

FIG. 19 Global Cancer Biological Therapy Market, by Immune Checkpoint Inhibitors, Value, 2017-2030 (US$ Mn)

FIG. 20 Global Cancer Biological Therapy Market, by Cytokines, Value, 2017-2030 (US$ Mn)

FIG. 21 Global Cancer Biological Therapy Market, by Cancer Vaccines, Value, 2017-2030 (US$ Mn)

FIG. 22 Global Cancer Biological Therapy Market, by Gene Therapy, Value, 2017-2030 (US$ Mn)

FIG. 23 Global Cancer Biological Therapy Market, by Oncolytic Viruses, Value, 2017-2030 (US$ Mn)

FIG. 24 Global Cancer Biological Therapy Market, by Others, Value, 2017-2030 (US$ Mn)

FIG. 25 Global Cancer Biological Therapy Market Value Contribution, By Cancer Type, 2022 & 2030 (Value %)

FIG. 26 Global Cancer Biological Therapy Market, by Breast Cancer, Value, 2017-2030 (US$ Mn)

FIG. 27 Global Cancer Biological Therapy Market, by Lung Cancer, Value, 2017-2030 (US$ Mn)

FIG. 28 Global Cancer Biological Therapy Market, by Colorectal Cancer, Value, 2017-2030 (US$ Mn)

FIG. 29 Global Cancer Biological Therapy Market, by Leukemia and Lymphoma, Value, 2017-2030 (US$ Mn)

FIG. 30 Global Cancer Biological Therapy Market, by Melanoma, Value, 2017-2030 (US$ Mn)

FIG. 31 Global Cancer Biological Therapy Market, by Prostate Cancer, Value, 2017-2030 (US$ Mn)

FIG. 32 Global Cancer Biological Therapy Market, by Other Cancer Types, Value, 2017-2030 (US$ Mn)

FIG. 33 Global Cancer Biological Therapy Market Value Contribution, By End User, 2022 & 2030 (Value %)

FIG. 34 Global Cancer Biological Therapy Market, by Hospitals, Value, 2017-2030 (US$ Mn)

FIG. 35 Global Cancer Biological Therapy Market, by Cancer Clinics, Value, 2017-2030 (US$ Mn)

FIG. 36 Global Cancer Biological Therapy Market, by Research Institutions, Value, 2017-2030 (US$ Mn)

FIG. 37 Global Cancer Biological Therapy Market Value Contribution, By Patient Demographics, 2022 & 2030 (Value %)

FIG. 38 Global Cancer Biological Therapy Market, by Pediatric, Value, 2017-2030 (US$ Mn)

FIG. 39 Global Cancer Biological Therapy Market, by Adult, Value, 2017-2030 (US$ Mn)

FIG. 40 North America Cancer Biological Therapy Market, 2017-2030 (US$ Mn)

FIG. 41 U.S. Cancer Biological Therapy Market, 2017-2030 (US$ Mn)

FIG. 42 Canada Cancer Biological Therapy Market, 2017-2030 (US$ Mn)

FIG. 43 Mexico Cancer Biological Therapy Market, 2017-2030 (US$ Mn)

FIG. 44 Europe Cancer Biological Therapy Market, 2017-2030 (US$ Mn)

FIG. 45 Germany Cancer Biological Therapy Market, 2017-2030 (US$ Mn)

FIG. 46 France Cancer Biological Therapy Market, 2017-2030 (US$ Mn)

FIG. 47 U.K. Cancer Biological Therapy Market, 2017-2030 (US$ Mn)

FIG. 48 Italy Cancer Biological Therapy Market, 2017-2030 (US$ Mn)

FIG. 49 Spain Cancer Biological Therapy Market, 2017-2030 (US$ Mn)

FIG. 50 Benelux Cancer Biological Therapy Market, 2017-2030 (US$ Mn)

FIG. 51 Russia Cancer Biological Therapy Market, 2017-2030 (US$ Mn)

FIG. 52 Rest of Europe Cancer Biological Therapy Market, 2017-2030 (US$ Mn)

FIG. 53 Asia Pacific Cancer Biological Therapy Market, 2017-2030 (US$ Mn)

FIG. 54 China Cancer Biological Therapy Market, 2017-2030 (US$ Mn)

FIG. 55 Japan Cancer Biological Therapy Market, 2017-2030 (US$ Mn)

FIG. 56 India Cancer Biological Therapy Market, 2017-2030 (US$ Mn)

FIG. 57 South Korea Cancer Biological Therapy Market, 2017-2030 (US$ Mn)

FIG. 58 South-East Asia Cancer Biological Therapy Market, 2017-2030 (US$ Mn)

FIG. 59 Rest of Asia Pacific Cancer Biological Therapy Market, 2017-2030 (US$ Mn)

FIG. 60 Latin America Cancer Biological Therapy Market, 2017-2030 (US$ Mn)

FIG. 61 Brazil Cancer Biological Therapy Market, 2017-2030 (US$ Mn)

FIG. 62 Argentina Cancer Biological Therapy Market, 2017-2030 (US$ Mn)

FIG. 63 Rest of Latin America Cancer Biological Therapy Market, 2017-2030 (US$ Mn)

FIG. 64 Middle East Cancer Biological Therapy Market, 2017-2030 (US$ Mn)

FIG. 65 UAE Cancer Biological Therapy Market, 2017-2030 (US$ Mn)

FIG. 66 Saudi Arabia Cancer Biological Therapy Market, 2017-2030 (US$ Mn)

FIG. 67 Rest of Middle East Cancer Biological Therapy Market, 2017-2030 (US$ Mn)

FIG. 68 Africa Cancer Biological Therapy Market, 2017-2030 (US$ Mn)

FIG. 69 South Africa Cancer Biological Therapy Market, 2017-2030 (US$ Mn)

FIG. 70 Egypt Cancer Biological Therapy Market, 2017-2030 (US$ Mn)

FIG. 71 Rest of Africa Cancer Biological Therapy Market, 2017-2030 (US$ Mn)

List of Tables

TABLE 1 Market Snapshot: Global Cancer Biological Therapy Market

TABLE 2 Global Cancer Biological Therapy Market: Market Drivers Impact Analysis

TABLE 3 Global Cancer Biological Therapy Market: Market Restraints Impact Analysis

TABLE 4 Global Cancer Biological Therapy Market, by Competitive Benchmarking, 2022

TABLE 5 Global Cancer Biological Therapy Market, by Geographical Presence Analysis, 2022

TABLE 6 Global Cancer Biological Therapy Market, by Key Strategies Analysis, 2022

TABLE 7 Global Cancer Biological Therapy Market, by Monoclonal Antibodies (mAbs), By Region, 2017-2022 (US$ Mn)

TABLE 8 Global Cancer Biological Therapy Market, by Monoclonal Antibodies (mAbs), By Region, 2023-2030 (US$ Mn)

TABLE 9 Global Cancer Biological Therapy Market, by Tyrosine Kinase Inhibitors (TKIs), By Region, 2017-2022 (US$ Mn)

TABLE 10 Global Cancer Biological Therapy Market, by Tyrosine Kinase Inhibitors (TKIs), By Region, 2023-2030 (US$ Mn)

TABLE 11 Global Cancer Biological Therapy Market, by Immune Checkpoint Inhibitors, By Region, 2017-2022 (US$ Mn)

TABLE 12 Global Cancer Biological Therapy Market, by Immune Checkpoint Inhibitors, By Region, 2023-2030 (US$ Mn)

TABLE 13 Global Cancer Biological Therapy Market, by Cytokines, By Region, 2017-2022 (US$ Mn)

TABLE 14 Global Cancer Biological Therapy Market, by Cytokines, By Region, 2023-2030 (US$ Mn)

TABLE 15 Global Cancer Biological Therapy Market, by Cancer Vaccines, By Region, 2017-2022 (US$ Mn)

TABLE 16 Global Cancer Biological Therapy Market, by Cancer Vaccines, By Region, 2023-2030 (US$ Mn)

TABLE 17 Global Cancer Biological Therapy Market, by Gene Therapy, By Region, 2017-2022 (US$ Mn)

TABLE 18 Global Cancer Biological Therapy Market, by Gene Therapy, By Region, 2023-2030 (US$ Mn)

TABLE 19 Global Cancer Biological Therapy Market, by Oncolytic Viruses, By Region, 2017-2022 (US$ Mn)

TABLE 20 Global Cancer Biological Therapy Market, by Oncolytic Viruses, By Region, 2023-2030 (US$ Mn)

TABLE 21 Global Cancer Biological Therapy Market, by Others, By Region, 2017-2022 (US$ Mn)

TABLE 22 Global Cancer Biological Therapy Market, by Others, By Region, 2023-2030 (US$ Mn)

TABLE 23 Global Cancer Biological Therapy Market, by Breast Cancer, By Region, 2017-2022 (US$ Mn)

TABLE 24 Global Cancer Biological Therapy Market, by Breast Cancer, By Region, 2023-2030 (US$ Mn)

TABLE 25 Global Cancer Biological Therapy Market, by Lung Cancer, By Region, 2017-2022 (US$ Mn)

TABLE 26 Global Cancer Biological Therapy Market, by Lung Cancer, By Region, 2023-2030 (US$ Mn)

TABLE 27 Global Cancer Biological Therapy Market, by Colorectal Cancer, By Region, 2017-2022 (US$ Mn)

TABLE 28 Global Cancer Biological Therapy Market, by Colorectal Cancer, By Region, 2023-2030 (US$ Mn)

TABLE 29 Global Cancer Biological Therapy Market, by Leukemia and Lymphoma, By Region, 2017-2022 (US$ Mn)

TABLE 30 Global Cancer Biological Therapy Market, by Leukemia and Lymphoma, By Region, 2023-2030 (US$ Mn)

TABLE 31 Global Cancer Biological Therapy Market, by Melanoma, By Region, 2017-2022 (US$ Mn)

TABLE 32 Global Cancer Biological Therapy Market, by Melanoma, By Region, 2023-2030 (US$ Mn)

TABLE 33 Global Cancer Biological Therapy Market, by Prostate Cancer, By Region, 2017-2022 (US$ Mn)

TABLE 34 Global Cancer Biological Therapy Market, by Prostate Cancer, By Region, 2023-2030 (US$ Mn)

TABLE 35 Global Cancer Biological Therapy Market, by Other Cancer Types, By Region, 2017-2022 (US$ Mn)

TABLE 36 Global Cancer Biological Therapy Market, by Other Cancer Types, By Region, 2023-2030 (US$ Mn)

TABLE 37 Global Cancer Biological Therapy Market, by Hospitals, By Region, 2017-2022 (US$ Mn)

TABLE 38 Global Cancer Biological Therapy Market, by Hospitals, By Region, 2023-2030 (US$ Mn)

TABLE 39 Global Cancer Biological Therapy Market, by Cancer Clinics, By Region, 2017-2022 (US$ Mn)

TABLE 40 Global Cancer Biological Therapy Market, by Cancer Clinics, By Region, 2023-2030 (US$ Mn)

TABLE 41 Global Cancer Biological Therapy Market, by Research Institutions, By Region, 2017-2022 (US$ Mn)

TABLE 42 Global Cancer Biological Therapy Market, by Research Institutions, By Region, 2023-2030 (US$ Mn)

TABLE 43 Global Cancer Biological Therapy Market, by Pediatric, By Region, 2017-2022 (US$ Mn)

TABLE 44 Global Cancer Biological Therapy Market, by Pediatric, By Region, 2023-2030 (US$ Mn)

TABLE 45 Global Cancer Biological Therapy Market, by Adult, By Region, 2017-2022 (US$ Mn)

TABLE 46 Global Cancer Biological Therapy Market, by Adult, By Region, 2023-2030 (US$ Mn)

TABLE 47 Global Cancer Biological Therapy Market, by Therapeutic Approach, 2017-2022 (US$ Mn)

TABLE 48 Global Cancer Biological Therapy Market, by Therapeutic Approach, 2023-2030 (US$ Mn)

TABLE 49 Global Cancer Biological Therapy Market, by Cancer Type, 2017-2022 (US$ Mn)

TABLE 50 Global Cancer Biological Therapy Market, by Cancer Type, 2023-2030 (US$ Mn)

TABLE 51 Global Cancer Biological Therapy Market, by End User, 2017-2022 (US$ Mn)

TABLE 52 Global Cancer Biological Therapy Market, by End User, 2023-2030 (US$ Mn)

TABLE 53 Global Cancer Biological Therapy Market, by Patient Demographics, 2017-2022 (US$ Mn)

TABLE 54 Global Cancer Biological Therapy Market, by Patient Demographics, 2023-2030 (US$ Mn)

TABLE 55 Global Cancer Biological Therapy Market, by Region, 2017-2022 (US$ Mn)

TABLE 56 Global Cancer Biological Therapy Market, by Region, 2023-2030 (US$ Mn)

TABLE 57 North America Cancer Biological Therapy Market, by Therapeutic Approach, 2017-2022 (US$ Mn)

TABLE 58 North America Cancer Biological Therapy Market, by Therapeutic Approach, 2023-2030 (US$ Mn)

TABLE 59 North America Cancer Biological Therapy Market, by Cancer Type, 2017-2022 (US$ Mn)

TABLE 60 North America Cancer Biological Therapy Market, by Cancer Type, 2023-2030 (US$ Mn)

TABLE 61 North America Cancer Biological Therapy Market, by End User, 2017-2022 (US$ Mn)

TABLE 62 North America Cancer Biological Therapy Market, by End User, 2023-2030 (US$ Mn)

TABLE 63 North America Cancer Biological Therapy Market, by Patient Demographics, 2017-2022 (US$ Mn)

TABLE 64 North America Cancer Biological Therapy Market, by Patient Demographics, 2023-2030 (US$ Mn)

TABLE 65 North America Cancer Biological Therapy Market, by Country, 2017-2022 (US$ Mn)

TABLE 66 North America Cancer Biological Therapy Market, by Country, 2023-2030 (US$ Mn)

TABLE 67 United States Cancer Biological Therapy Market, by Therapeutic Approach, 2017-2022 (US$ Mn)

TABLE 68 United States Cancer Biological Therapy Market, by Therapeutic Approach, 2023-2030 (US$ Mn)

TABLE 69 United States Cancer Biological Therapy Market, by Cancer Type, 2017-2022 (US$ Mn)

TABLE 70 United States Cancer Biological Therapy Market, by Cancer Type, 2023-2030 (US$ Mn)

TABLE 71 United States Cancer Biological Therapy Market, by End User, 2017-2022 (US$ Mn)

TABLE 72 United States Cancer Biological Therapy Market, by End User, 2023-2030 (US$ Mn)

TABLE 73 United States Cancer Biological Therapy Market, by Patient Demographics, 2017-2022 (US$ Mn)

TABLE 74 United States Cancer Biological Therapy Market, by Patient Demographics, 2023-2030 (US$ Mn)

TABLE 75 Canada Cancer Biological Therapy Market, by Therapeutic Approach, 2017-2022 (US$ Mn)

TABLE 76 Canada Cancer Biological Therapy Market, by Therapeutic Approach, 2023-2030 (US$ Mn)

TABLE 77 Canada Cancer Biological Therapy Market, by Cancer Type, 2017-2022 (US$ Mn)

TABLE 78 Canada Cancer Biological Therapy Market, by Cancer Type, 2023-2030 (US$ Mn)

TABLE 79 Canada Cancer Biological Therapy Market, by End User, 2017-2022 (US$ Mn)

TABLE 80 Canada Cancer Biological Therapy Market, by End User, 2023-2030 (US$ Mn)

TABLE 81 Canada Cancer Biological Therapy Market, by Patient Demographics, 2017-2022 (US$ Mn)

TABLE 82 Canada Cancer Biological Therapy Market, by Patient Demographics, 2023-2030 (US$ Mn)

TABLE 83 Mexico Cancer Biological Therapy Market, by Therapeutic Approach, 2017-2022 (US$ Mn)

TABLE 84 Mexico Cancer Biological Therapy Market, by Therapeutic Approach, 2023-2030 (US$ Mn)

TABLE 85 Mexico Cancer Biological Therapy Market, by Cancer Type, 2017-2022 (US$ Mn)

TABLE 86 Mexico Cancer Biological Therapy Market, by Cancer Type, 2023-2030 (US$ Mn)

TABLE 87 Mexico Cancer Biological Therapy Market, by End User, 2017-2022 (US$ Mn)

TABLE 88 Mexico Cancer Biological Therapy Market, by End User, 2023-2030 (US$ Mn)

TABLE 89 Mexico Cancer Biological Therapy Market, by Patient Demographics, 2017-2022 (US$ Mn)

TABLE 90 Mexico Cancer Biological Therapy Market, by Patient Demographics, 2023-2030 (US$ Mn)

TABLE 91 Europe Cancer Biological Therapy Market, by Therapeutic Approach, 2017-2022 (US$ Mn)

TABLE 92 Europe Cancer Biological Therapy Market, by Therapeutic Approach, 2023-2030 (US$ Mn)

TABLE 93 Europe Cancer Biological Therapy Market, by Cancer Type, 2017-2022 (US$ Mn)

TABLE 94 Europe Cancer Biological Therapy Market, by Cancer Type, 2023-2030 (US$ Mn)

TABLE 95 Europe Cancer Biological Therapy Market, by End User, 2017-2022 (US$ Mn)

TABLE 96 Europe Cancer Biological Therapy Market, by End User, 2023-2030 (US$ Mn)

TABLE 97 Europe Cancer Biological Therapy Market, by Patient Demographics, 2017-2022 (US$ Mn)

TABLE 98 Europe Cancer Biological Therapy Market, by Patient Demographics, 2023-2030 (US$ Mn)

TABLE 99 Europe Cancer Biological Therapy Market, by Country, 2017-2022 (US$ Mn)

TABLE 100 Europe Cancer Biological Therapy Market, by Country, 2023-2030 (US$ Mn)

TABLE 101 Germany Cancer Biological Therapy Market, by Therapeutic Approach, 2017-2022 (US$ Mn)

TABLE 102 Germany Cancer Biological Therapy Market, by Therapeutic Approach, 2023-2030 (US$ Mn)

TABLE 103 Germany Cancer Biological Therapy Market, by Cancer Type, 2017-2022 (US$ Mn)

TABLE 104 Germany Cancer Biological Therapy Market, by Cancer Type, 2023-2030 (US$ Mn)

TABLE 105 Germany Cancer Biological Therapy Market, by End User, 2017-2022 (US$ Mn)

TABLE 106 Germany Cancer Biological Therapy Market, by End User, 2023-2030 (US$ Mn)

TABLE 107 Germany Cancer Biological Therapy Market, by Patient Demographics, 2017-2022 (US$ Mn)

TABLE 108 Germany Cancer Biological Therapy Market, by Patient Demographics, 2023-2030 (US$ Mn)

TABLE 109 France Cancer Biological Therapy Market, by Therapeutic Approach, 2017-2022 (US$ Mn)

TABLE 110 France Cancer Biological Therapy Market, by Therapeutic Approach, 2023-2030 (US$ Mn)

TABLE 111 France Cancer Biological Therapy Market, by Cancer Type, 2017-2022 (US$ Mn)

TABLE 112 France Cancer Biological Therapy Market, by Cancer Type, 2023-2030 (US$ Mn)

TABLE 113 France Cancer Biological Therapy Market, by End User, 2017-2022 (US$ Mn)

TABLE 114 France Cancer Biological Therapy Market, by End User, 2023-2030 (US$ Mn)

TABLE 115 France Cancer Biological Therapy Market, by Patient Demographics, 2017-2022 (US$ Mn)

TABLE 116 France Cancer Biological Therapy Market, by Patient Demographics, 2023-2030 (US$ Mn)

TABLE 117 United Kingdom Cancer Biological Therapy Market, by Therapeutic Approach, 2017-2022 (US$ Mn)

TABLE 118 United Kingdom Cancer Biological Therapy Market, by Therapeutic Approach, 2023-2030 (US$ Mn)

TABLE 119 United Kingdom Cancer Biological Therapy Market, by Cancer Type, 2017-2022 (US$ Mn)

TABLE 120 United Kingdom Cancer Biological Therapy Market, by Cancer Type, 2023-2030 (US$ Mn)

TABLE 121 United Kingdom Cancer Biological Therapy Market, by End User, 2017-2022 (US$ Mn)

TABLE 122 United Kingdom Cancer Biological Therapy Market, by End User, 2023-2030 (US$ Mn)

TABLE 123 United Kingdom Cancer Biological Therapy Market, by Patient Demographics, 2017-2022 (US$ Mn)

TABLE 124 United Kingdom Cancer Biological Therapy Market, by Patient Demographics, 2023-2030 (US$ Mn)

TABLE 125 Italy Cancer Biological Therapy Market, by Therapeutic Approach, 2017-2022 (US$ Mn)

TABLE 126 Italy Cancer Biological Therapy Market, by Therapeutic Approach, 2023-2030 (US$ Mn)

TABLE 127 Italy Cancer Biological Therapy Market, by Cancer Type, 2017-2022 (US$ Mn)

TABLE 128 Italy Cancer Biological Therapy Market, by Cancer Type, 2023-2030 (US$ Mn)

TABLE 129 Italy Cancer Biological Therapy Market, by End User, 2017-2022 (US$ Mn)

TABLE 130 Italy Cancer Biological Therapy Market, by End User, 2023-2030 (US$ Mn)

TABLE 131 Italy Cancer Biological Therapy Market, by Patient Demographics, 2017-2022 (US$ Mn)

TABLE 132 Italy Cancer Biological Therapy Market, by Patient Demographics, 2023-2030 (US$ Mn)

TABLE 133 Spain Cancer Biological Therapy Market, by Therapeutic Approach, 2017-2022 (US$ Mn)

TABLE 134 Spain Cancer Biological Therapy Market, by Therapeutic Approach, 2023-2030 (US$ Mn)

TABLE 135 Spain Cancer Biological Therapy Market, by Cancer Type, 2017-2022 (US$ Mn)

TABLE 136 Spain Cancer Biological Therapy Market, by Cancer Type, 2023-2030 (US$ Mn)

TABLE 137 Spain Cancer Biological Therapy Market, by End User, 2017-2022 (US$ Mn)

TABLE 138 Spain Cancer Biological Therapy Market, by End User, 2023-2030 (US$ Mn)

TABLE 139 Spain Cancer Biological Therapy Market, by Patient Demographics, 2017-2022 (US$ Mn)

TABLE 140 Spain Cancer Biological Therapy Market, by Patient Demographics, 2023-2030 (US$ Mn)

TABLE 141 Benelux Cancer Biological Therapy Market, by Therapeutic Approach, 2017-2022 (US$ Mn)

TABLE 142 Benelux Cancer Biological Therapy Market, by Therapeutic Approach, 2023-2030 (US$ Mn)

TABLE 143 Benelux Cancer Biological Therapy Market, by Cancer Type, 2017-2022 (US$ Mn)

TABLE 144 Benelux Cancer Biological Therapy Market, by Cancer Type, 2023-2030 (US$ Mn)

TABLE 145 Benelux Cancer Biological Therapy Market, by End User, 2017-2022 (US$ Mn)

TABLE 146 Benelux Cancer Biological Therapy Market, by End User, 2023-2030 (US$ Mn)

TABLE 147 Benelux Cancer Biological Therapy Market, by Patient Demographics, 2017-2022 (US$ Mn)

TABLE 148 Benelux Cancer Biological Therapy Market, by Patient Demographics, 2023-2030 (US$ Mn)

TABLE 149 Russia Cancer Biological Therapy Market, by Therapeutic Approach, 2017-2022 (US$ Mn)

TABLE 150 Russia Cancer Biological Therapy Market, by Therapeutic Approach, 2023-2030 (US$ Mn)

TABLE 151 Russia Cancer Biological Therapy Market, by Cancer Type, 2017-2022 (US$ Mn)

TABLE 152 Russia Cancer Biological Therapy Market, by Cancer Type, 2023-2030 (US$ Mn)

TABLE 153 Russia Cancer Biological Therapy Market, by End User, 2017-2022 (US$ Mn)

TABLE 154 Russia Cancer Biological Therapy Market, by End User, 2023-2030 (US$ Mn)

TABLE 155 Russia Cancer Biological Therapy Market, by Patient Demographics, 2017-2022 (US$ Mn)

TABLE 156 Russia Cancer Biological Therapy Market, by Patient Demographics, 2023-2030 (US$ Mn)

TABLE 157 Rest of Europe Cancer Biological Therapy Market, by Therapeutic Approach, 2017-2022 (US$ Mn)

TABLE 158 Rest of Europe Cancer Biological Therapy Market, by Therapeutic Approach, 2023-2030 (US$ Mn)

TABLE 159 Rest of Europe Cancer Biological Therapy Market, by Cancer Type, 2017-2022 (US$ Mn)

TABLE 160 Rest of Europe Cancer Biological Therapy Market, by Cancer Type, 2023-2030 (US$ Mn)

TABLE 161 Rest of Europe Cancer Biological Therapy Market, by End User, 2017-2022 (US$ Mn)

TABLE 162 Rest of Europe Cancer Biological Therapy Market, by End User, 2023-2030 (US$ Mn)

TABLE 163 Rest of Europe Cancer Biological Therapy Market, by Patient Demographics, 2017-2022 (US$ Mn)

TABLE 164 Rest of Europe Cancer Biological Therapy Market, by Patient Demographics, 2023-2030 (US$ Mn)

TABLE 165 Asia Pacific Cancer Biological Therapy Market, by Therapeutic Approach, 2017-2022 (US$ Mn)

TABLE 166 Asia Pacific Cancer Biological Therapy Market, by Therapeutic Approach, 2023-2030 (US$ Mn)

TABLE 167 Asia Pacific Cancer Biological Therapy Market, by Cancer Type, 2017-2022 (US$ Mn)

TABLE 168 Asia Pacific Cancer Biological Therapy Market, by Cancer Type, 2023-2030 (US$ Mn)

TABLE 169 Asia Pacific Cancer Biological Therapy Market, by End User, 2017-2022 (US$ Mn)

TABLE 170 Asia Pacific Cancer Biological Therapy Market, by End User, 2023-2030 (US$ Mn)

TABLE 171 Asia Pacific Cancer Biological Therapy Market, by Patient Demographics, 2017-2022 (US$ Mn)

TABLE 172 Asia Pacific Cancer Biological Therapy Market, by Patient Demographics, 2023-2030 (US$ Mn)

TABLE 173 China Cancer Biological Therapy Market, by Therapeutic Approach, 2017-2022 (US$ Mn)

TABLE 174 China Cancer Biological Therapy Market, by Therapeutic Approach, 2023-2030 (US$ Mn)

TABLE 175 China Cancer Biological Therapy Market, by Cancer Type, 2017-2022 (US$ Mn)

TABLE 176 China Cancer Biological Therapy Market, by Cancer Type, 2023-2030 (US$ Mn)

TABLE 177 China Cancer Biological Therapy Market, by End User, 2017-2022 (US$ Mn)

TABLE 178 China Cancer Biological Therapy Market, by End User, 2023-2030 (US$ Mn)

TABLE 179 China Cancer Biological Therapy Market, by Patient Demographics, 2017-2022 (US$ Mn)

TABLE 180 China Cancer Biological Therapy Market, by Patient Demographics, 2023-2030 (US$ Mn)

TABLE 181 Japan Cancer Biological Therapy Market, by Therapeutic Approach, 2017-2022 (US$ Mn)

TABLE 182 Japan Cancer Biological Therapy Market, by Therapeutic Approach, 2023-2030 (US$ Mn)

TABLE 183 Japan Cancer Biological Therapy Market, by Cancer Type, 2017-2022 (US$ Mn)

TABLE 184 Japan Cancer Biological Therapy Market, by Cancer Type, 2023-2030 (US$ Mn)

TABLE 185 Japan Cancer Biological Therapy Market, by End User, 2017-2022 (US$ Mn)

TABLE 186 Japan Cancer Biological Therapy Market, by End User, 2023-2030 (US$ Mn)

TABLE 187 Japan Cancer Biological Therapy Market, by Patient Demographics, 2017-2022 (US$ Mn)

TABLE 188 Japan Cancer Biological Therapy Market, by Patient Demographics, 2023-2030 (US$ Mn)

TABLE 189 India Cancer Biological Therapy Market, by Therapeutic Approach, 2017-2022 (US$ Mn)

TABLE 190 India Cancer Biological Therapy Market, by Therapeutic Approach, 2023-2030 (US$ Mn)

TABLE 191 India Cancer Biological Therapy Market, by Cancer Type, 2017-2022 (US$ Mn)

TABLE 192 India Cancer Biological Therapy Market, by Cancer Type, 2023-2030 (US$ Mn)

TABLE 193 India Cancer Biological Therapy Market, by End User, 2017-2022 (US$ Mn)

TABLE 194 India Cancer Biological Therapy Market, by End User, 2023-2030 (US$ Mn)

TABLE 195 India Cancer Biological Therapy Market, by Patient Demographics, 2017-2022 (US$ Mn)

TABLE 196 India Cancer Biological Therapy Market, by Patient Demographics, 2023-2030 (US$ Mn)

TABLE 197 South Korea Cancer Biological Therapy Market, by Therapeutic Approach, 2017-2022 (US$ Mn)

TABLE 198 South Korea Cancer Biological Therapy Market, by Therapeutic Approach, 2023-2030 (US$ Mn)

TABLE 199 South Korea Cancer Biological Therapy Market, by Cancer Type, 2017-2022 (US$ Mn)

TABLE 200 South Korea Cancer Biological Therapy Market, by Cancer Type, 2023-2030 (US$ Mn)

TABLE 201 South Korea Cancer Biological Therapy Market, by End User, 2017-2022 (US$ Mn)

TABLE 202 South Korea Cancer Biological Therapy Market, by End User, 2023-2030 (US$ Mn)

TABLE 203 South Korea Cancer Biological Therapy Market, by Patient Demographics, 2017-2022 (US$ Mn)

TABLE 204 South Korea Cancer Biological Therapy Market, by Patient Demographics, 2023-2030 (US$ Mn)

TABLE 205 South-East Asia Cancer Biological Therapy Market, by Therapeutic Approach, 2017-2022 (US$ Mn)

TABLE 206 South-East Asia Cancer Biological Therapy Market, by Therapeutic Approach, 2023-2030 (US$ Mn)

TABLE 207 South-East Asia Cancer Biological Therapy Market, by Cancer Type, 2017-2022 (US$ Mn)

TABLE 208 South-East Asia Cancer Biological Therapy Market, by Cancer Type, 2023-2030 (US$ Mn)

TABLE 209 South-East Asia Cancer Biological Therapy Market, by End User, 2017-2022 (US$ Mn)

TABLE 210 South-East Asia Cancer Biological Therapy Market, by End User, 2023-2030 (US$ Mn)

TABLE 211 South-East Asia Cancer Biological Therapy Market, by Patient Demographics, 2017-2022 (US$ Mn)

TABLE 212 South-East Asia Cancer Biological Therapy Market, by Patient Demographics, 2023-2030 (US$ Mn)

TABLE 213 Rest of Asia Pacific Cancer Biological Therapy Market, by Therapeutic Approach, 2017-2022 (US$ Mn)

TABLE 214 Rest of Asia Pacific Cancer Biological Therapy Market, by Therapeutic Approach, 2023-2030 (US$ Mn)

TABLE 215 Rest of Asia Pacific Cancer Biological Therapy Market, by Cancer Type, 2017-2022 (US$ Mn)

TABLE 216 Rest of Asia Pacific Cancer Biological Therapy Market, by Cancer Type, 2023-2030 (US$ Mn)

TABLE 217 Rest of Asia Pacific Cancer Biological Therapy Market, by End User, 2017-2022 (US$ Mn)

TABLE 218 Rest of Asia Pacific Cancer Biological Therapy Market, by End User, 2023-2030 (US$ Mn)

TABLE 219 Rest of Asia Pacific Cancer Biological Therapy Market, by Patient Demographics, 2017-2022 (US$ Mn)

TABLE 220 Rest of Asia Pacific Cancer Biological Therapy Market, by Patient Demographics, 2023-2030 (US$ Mn)

TABLE 221 Latin America Cancer Biological Therapy Market, by Therapeutic Approach, 2017-2022 (US$ Mn)

TABLE 222 Latin America Cancer Biological Therapy Market, by Therapeutic Approach, 2023-2030 (US$ Mn)

TABLE 223 Latin America Cancer Biological Therapy Market, by Cancer Type, 2017-2022 (US$ Mn)

TABLE 224 Latin America Cancer Biological Therapy Market, by Cancer Type, 2023-2030 (US$ Mn)

TABLE 225 Latin America Cancer Biological Therapy Market, by End User, 2017-2022 (US$ Mn)

TABLE 226 Latin America Cancer Biological Therapy Market, by End User, 2023-2030 (US$ Mn)

TABLE 227 Latin America Cancer Biological Therapy Market, by Patient Demographics, 2017-2022 (US$ Mn)

TABLE 228 Latin America Cancer Biological Therapy Market, by Patient Demographics, 2023-2030 (US$ Mn)

TABLE 229 Brazil Cancer Biological Therapy Market, by Therapeutic Approach, 2017-2022 (US$ Mn)

TABLE 230 Brazil Cancer Biological Therapy Market, by Therapeutic Approach, 2023-2030 (US$ Mn)

TABLE 231 Brazil Cancer Biological Therapy Market, by Cancer Type, 2017-2022 (US$ Mn)

TABLE 232 Brazil Cancer Biological Therapy Market, by Cancer Type, 2023-2030 (US$ Mn)

TABLE 233 Brazil Cancer Biological Therapy Market, by End User, 2017-2022 (US$ Mn)

TABLE 234 Brazil Cancer Biological Therapy Market, by End User, 2023-2030 (US$ Mn)

TABLE 235 Brazil Cancer Biological Therapy Market, by Patient Demographics, 2017-2022 (US$ Mn)

TABLE 236 Brazil Cancer Biological Therapy Market, by Patient Demographics, 2023-2030 (US$ Mn)

TABLE 237 Argentina Cancer Biological Therapy Market, by Therapeutic Approach, 2017-2022 (US$ Mn)

TABLE 238 Argentina Cancer Biological Therapy Market, by Therapeutic Approach, 2023-2030 (US$ Mn)

TABLE 239 Argentina Cancer Biological Therapy Market, by Cancer Type, 2017-2022 (US$ Mn)

TABLE 240 Argentina Cancer Biological Therapy Market, by Cancer Type, 2023-2030 (US$ Mn)

TABLE 241 Argentina Cancer Biological Therapy Market, by End User, 2017-2022 (US$ Mn)

TABLE 242 Argentina Cancer Biological Therapy Market, by End User, 2023-2030 (US$ Mn)

TABLE 243 Argentina Cancer Biological Therapy Market, by Patient Demographics, 2017-2022 (US$ Mn)

TABLE 244 Argentina Cancer Biological Therapy Market, by Patient Demographics, 2023-2030 (US$ Mn)

TABLE 245 Rest of Latin America Cancer Biological Therapy Market, by Therapeutic Approach, 2017-2022 (US$ Mn)

TABLE 246 Rest of Latin America Cancer Biological Therapy Market, by Therapeutic Approach, 2023-2030 (US$ Mn)

TABLE 247 Rest of Latin America Cancer Biological Therapy Market, by Cancer Type, 2017-2022 (US$ Mn)

TABLE 248 Rest of Latin America Cancer Biological Therapy Market, by Cancer Type, 2023-2030 (US$ Mn)

TABLE 249 Rest of Latin America Cancer Biological Therapy Market, by End User, 2017-2022 (US$ Mn)

TABLE 250 Rest of Latin America Cancer Biological Therapy Market, by End User, 2023-2030 (US$ Mn)

TABLE 251 Rest of Latin America Cancer Biological Therapy Market, by Patient Demographics, 2017-2022 (US$ Mn)

TABLE 252 Rest of Latin America Cancer Biological Therapy Market, by Patient Demographics, 2023-2030 (US$ Mn)

TABLE 253 Middle East Cancer Biological Therapy Market, by Therapeutic Approach, 2017-2022 (US$ Mn)

TABLE 254 Middle East Cancer Biological Therapy Market, by Therapeutic Approach, 2023-2030 (US$ Mn)

TABLE 255 Middle East Cancer Biological Therapy Market, by Cancer Type, 2017-2022 (US$ Mn)

TABLE 256 Middle East Cancer Biological Therapy Market, by Cancer Type, 2023-2030 (US$ Mn)

TABLE 257 Middle East Cancer Biological Therapy Market, by End User, 2017-2022 (US$ Mn)

TABLE 258 Middle East Cancer Biological Therapy Market, by End User, 2023-2030 (US$ Mn)

TABLE 259 Middle East Cancer Biological Therapy Market, by Patient Demographics, 2017-2022 (US$ Mn)

TABLE 260 Middle East Cancer Biological Therapy Market, by Patient Demographics, 2023-2030 (US$ Mn)

TABLE 261 UAE Cancer Biological Therapy Market, by Therapeutic Approach, 2017-2022 (US$ Mn)

TABLE 262 UAE Cancer Biological Therapy Market, by Therapeutic Approach, 2023-2030 (US$ Mn)

TABLE 263 UAE Cancer Biological Therapy Market, by Cancer Type, 2017-2022 (US$ Mn)

TABLE 264 UAE Cancer Biological Therapy Market, by Cancer Type, 2023-2030 (US$ Mn)

TABLE 265 UAE Cancer Biological Therapy Market, by End User, 2017-2022 (US$ Mn)

TABLE 266 UAE Cancer Biological Therapy Market, by End User, 2023-2030 (US$ Mn)

TABLE 267 UAE Cancer Biological Therapy Market, by Patient Demographics, 2017-2022 (US$ Mn)

TABLE 268 UAE Cancer Biological Therapy Market, by Patient Demographics, 2023-2030 (US$ Mn)

TABLE 269 Saudi Arabia Cancer Biological Therapy Market, by Therapeutic Approach, 2017-2022 (US$ Mn)

TABLE 270 Saudi Arabia Cancer Biological Therapy Market, by Therapeutic Approach, 2023-2030 (US$ Mn)

TABLE 271 Saudi Arabia Cancer Biological Therapy Market, by Cancer Type, 2017-2022 (US$ Mn)

TABLE 272 Saudi Arabia Cancer Biological Therapy Market, by Cancer Type, 2023-2030 (US$ Mn)

TABLE 273 Saudi Arabia Cancer Biological Therapy Market, by End User, 2017-2022 (US$ Mn)

TABLE 274 Saudi Arabia Cancer Biological Therapy Market, by End User, 2023-2030 (US$ Mn)

TABLE 275 Saudi Arabia Cancer Biological Therapy Market, by Patient Demographics, 2017-2022 (US$ Mn)

TABLE 276 Saudi Arabia Cancer Biological Therapy Market, by Patient Demographics, 2023-2030 (US$ Mn)

TABLE 277 Rest of Middle East Cancer Biological Therapy Market, by Therapeutic Approach, 2017-2022 (US$ Mn)

TABLE 278 Rest of Middle East Cancer Biological Therapy Market, by Therapeutic Approach, 2023-2030 (US$ Mn)

TABLE 279 Rest of Middle East Cancer Biological Therapy Market, by Cancer Type, 2017-2022 (US$ Mn)

TABLE 280 Rest of Middle East Cancer Biological Therapy Market, by Cancer Type, 2023-2030 (US$ Mn)

TABLE 281 Rest of Middle East Cancer Biological Therapy Market, by End User, 2017-2022 (US$ Mn)

TABLE 282 Rest of Middle East Cancer Biological Therapy Market, by End User, 2023-2030 (US$ Mn)

TABLE 283 Rest of Middle East Cancer Biological Therapy Market, by Patient Demographics, 2017-2022 (US$ Mn)

TABLE 284 Rest of Middle East Cancer Biological Therapy Market, by Patient Demographics, 2023-2030 (US$ Mn)

TABLE 285 Africa Cancer Biological Therapy Market, by Therapeutic Approach, 2017-2022 (US$ Mn)

TABLE 286 Africa Cancer Biological Therapy Market, by Therapeutic Approach, 2023-2030 (US$ Mn)

TABLE 287 Africa Cancer Biological Therapy Market, by Cancer Type, 2017-2022 (US$ Mn)

TABLE 288 Africa Cancer Biological Therapy Market, by Cancer Type, 2023-2030 (US$ Mn)

TABLE 289 Africa Cancer Biological Therapy Market, by End User, 2017-2022 (US$ Mn)

TABLE 290 Africa Cancer Biological Therapy Market, by End User, 2023-2030 (US$ Mn)

TABLE 291 Africa Cancer Biological Therapy Market, by Patient Demographics, 2017-2022 (US$ Mn)

TABLE 292 Africa Cancer Biological Therapy Market, by Patient Demographics, 2023-2030 (US$ Mn)

TABLE 293 South Africa Cancer Biological Therapy Market, by Therapeutic Approach, 2017-2022 (US$ Mn)

TABLE 294 South Africa Cancer Biological Therapy Market, by Therapeutic Approach, 2023-2030 (US$ Mn)

TABLE 295 South Africa Cancer Biological Therapy Market, by Cancer Type, 2017-2022 (US$ Mn)

TABLE 296 South Africa Cancer Biological Therapy Market, by Cancer Type, 2023-2030 (US$ Mn)

TABLE 297 South Africa Cancer Biological Therapy Market, by End User, 2017-2022 (US$ Mn)

TABLE 298 South Africa Cancer Biological Therapy Market, by End User, 2023-2030 (US$ Mn)

TABLE 299 South Africa Cancer Biological Therapy Market, by Patient Demographics, 2017-2022 (US$ Mn)

TABLE 300 South Africa Cancer Biological Therapy Market, by Patient Demographics, 2023-2030 (US$ Mn)

TABLE 301 Egypt Cancer Biological Therapy Market, by Therapeutic Approach, 2017-2022 (US$ Mn)

TABLE 302 Egypt Cancer Biological Therapy Market, by Therapeutic Approach, 2023-2030 (US$ Mn)

TABLE 303 Egypt Cancer Biological Therapy Market, by Cancer Type, 2017-2022 (US$ Mn)

TABLE 304 Egypt Cancer Biological Therapy Market, by Cancer Type, 2023-2030 (US$ Mn)

TABLE 305 Egypt Cancer Biological Therapy Market, by End User, 2017-2022 (US$ Mn)

TABLE 306 Egypt Cancer Biological Therapy Market, by End User, 2023-2030 (US$ Mn)

TABLE 307 Egypt Cancer Biological Therapy Market, by Patient Demographics, 2017-2022 (US$ Mn)

TABLE 308 Egypt Cancer Biological Therapy Market, by Patient Demographics, 2023-2030 (US$ Mn)

TABLE 309 Rest of Africa Cancer Biological Therapy Market, by Therapeutic Approach, 2017-2022 (US$ Mn)

TABLE 310 Rest of Africa Cancer Biological Therapy Market, by Therapeutic Approach, 2023-2030 (US$ Mn)

TABLE 311 Rest of Africa Cancer Biological Therapy Market, by Cancer Type, 2017-2022 (US$ Mn)

TABLE 312 Rest of Africa Cancer Biological Therapy Market, by Cancer Type, 2023-2030 (US$ Mn)

TABLE 313 Rest of Africa Cancer Biological Therapy Market, by End User, 2017-2022 (US$ Mn)

TABLE 314 Rest of Africa Cancer Biological Therapy Market, by End User, 2023-2030 (US$ Mn)

TABLE 315 Rest of Africa Cancer Biological Therapy Market, by Patient Demographics, 2017-2022 (US$ Mn)

TABLE 316 Rest of Africa Cancer Biological Therapy Market, by Patient Demographics, 2023-2030 (US$ Mn)

Frequently Asked Questions

What is the current size of the global cancer biological therapy market?

The global cancer biological therapy market was valued at USD 111945.8 Million in 2022.

What is the expected growth rate of the cancer biological therapy market between 2023 and 2030?

The cancer biological therapy market is expected to grow at a CAGR of 7.5% between 2023 and 2030, reaching USD 199652.8 Million in 2030.

Which segment is leading the market share in terms of therapeutic approach?

Monoclonal antibodies (mAbs) are the leading segment by therapeutic approach, holding over 30% share in value in 2022.

Which cancer type segment governs the global demand for cancer biological therapy?

The breast cancer segment governs the global demand for cancer biological therapy, holding a massive market share of over 25% in 2022.

Which end-user segment will post the highest CAGR in the forecast period?

The cancer clinics segment will post the highest CAGR over the projection period.

Which region is fueling the growth of the cancer biological therapy industry?

North America is propelling the rapid expansion of the cancer biological therapy industry, accounting for more than one-third of its market share in 2022.

Who are the major players in the global cancer biological therapy market?

The top players include F. Hoffmann-La Roche Ltd, Mylan N.V., Teva Pharmaceutical Industries Ltd, Sanofi, Pfizer Inc, GSK Plc, Novartis AG, Bayer AG, Merck & Co. Inc, Sun Pharmaceutical Industries Ltd, Aurobindo Pharma, Lupin, Endo Pharmaceuticals Plc, Zydus Group, Bausch Health Companies Inc, and Others.

What are the major market drivers of the cancer biological therapy industry?

The primary market drivers of the cancer biological therapy industry include developments in immunotherapy and precision medicine, rising cases of cancer, and expanding applicability across multiple cancer types.

What are the major market restraints of the cancer biological therapy industry?

The major market restraints of the cancer biological therapy industry encompass high treatment costs and regulatory challenges, hindering accessibility and adoption.

What are the major market opportunities of the cancer biological therapy industry?

The major market opportunities in the cancer biological therapy industry involve expanding applications to various cancer types and exploring combination therapies, along with addressing the unmet medical needs of pediatric patients and emerging markets in regions like the Asia Pacific.

Purchase Options

Request Free Sample

Have a question?

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –